Because CDK7 transcriptional kinase activity is regulated by HER2 and a series of receptor tyrosine kinases activated by HER2 inhibition, and by the downstream SHP2 and PI3K/AKT pathway, dual HER2 and CDK7 inhibition can overcome the therapy resistance of HER2-positive breast cancer and induce significant tumor regression in vivo (Sun et al., 2020). Here, ERBB2 is linked to breast carcinoma.